✦ LIBER ✦

Rationale and Design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and Its Outcomes) 3-4 Study

✍ Scribed by Vicente E. Torres; Esther Meijer; Kyongtae T. Bae; Arlene B. Chapman; Olivier Devuyst; Ron T. Gansevoort; Jared J. Grantham; Eiji Higashihara; Ronald D. Perrone; Holly B. Krasa; John J. Ouyang; Frank S. Czerwiec

Book ID: 114470121
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 418 KB
Volume: 57
Category: Article
ISSN: 0272-6386
DOI: 10.1053/j.ajkd.2010.11.029

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Rationale and Design of the DIPAK 1 Stud

Rationale and Design of the DIPAK 1 Study: A Randomized Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal Dominant Polycystic Kidney Disease

✍ Meijer, Esther; Drenth, Joost P.H.; d'Agnolo, Hedwig; Casteleijn, Niek F.; de Fi 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 255 KB

Isn’t It Ironic? Cost-Effectiveness and

Isn’t It Ironic? Cost-Effectiveness and Willingness to Pay for Tolvaptan in the Prevention of Kidney Failure in Autosomal Dominant Polycystic Kidney Disease

✍ Nee, Robert; Yuan, Christina M.; Abbott, Kevin C. 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Rationale and design of the RESOLVE tria

Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease

✍ Gevers, Tom JG; Chrispijn, Melissa; Wetzels, Jack FM; Drenth, Joost PH 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 164 KB

Design and baseline characteristics of p

Design and baseline characteristics of participants in the study of antihypertensive therapy in children and adolescents with autosomal dominant polycystic kidney disease (ADPKD)

✍ Melissa A. Cadnapaphornchai; Godela M. Fick-Brosnahan; Irene Duley; Ann M. Johns 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 126 KB